N/A N=195 Randomized Single-blind Health Services Research

Connect.Parkinson: Connecting Individuals With Parkinson Disease to Specialists in Their Homes

Parkinson Disease

Bottom Line

View on ClinicalTrials.gov: NCT02038959 ↗

Enrolled (actual)

195

Serious AEs

0.0%

Results posted

Jan 2017

Primary outcome: Primary: Feasibility of Virtual Visits for Parkinson Disease — 0; 95 participants

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Virtual Visits (Other)
Age: Adult, Older Adult · 30+ yrs
Sex: All
Sponsor: University of Rochester
Primary completion: Aug 2016

Outcome Measures

Outcome	Result	p-value
PRIMARY Feasibility of Virtual Visits for Parkinson Disease	0; 95	—
PRIMARY Change From Baseline in the Quality of Life Measured by Parkinson Disease Questionnaire 39	-0.7512; -0.4123	>0.05
SECONDARY Change in EQ-5D Index Value	-0.04122; -0.02728	—
SECONDARY Change in Montreal Cognition Assessment	0.2072; 0.6485	—
SECONDARY Change in Parkinson Disease Rating Scale (MDS-UPDRS) Part IA	-1.0122; -0.8546	—
SECONDARY Change in Patient Assessment of Chronic Illness Care	0.2456; 0.2795	—
SECONDARY Minutes Spend on Last Parkinson's Disease Provider Visit	30; 30	<0.0001 sig
SECONDARY Change in Parkinson Disease Rating Scale (MDS-UPDRS) Part IB	0.389; 0.1243	—
SECONDARY Change in Parkinson Disease Rating Scale (MDS-UPDRS) Part 2	-0.3266; 0.1378	—
SECONDARY Change in Parkinson Disease Rating Scale (MDS-UPDRS) Part 3	-4.9164; -5.7495	—
SECONDARY Change in Parkinson Disease Rating Scale (MDS-UPDRS) Part 4	-0.2075; -0.1825	—

Summary

Connect.Parkinson is a randomized comparative effectiveness study, comparing usual care enhanced with educational materials to usual care, educational materials, and the delivery of specialty care via telemedicine into patient's homes. The study's specific aims are the following: 1. To demonstrate the feasibility of using telemedicine to deliver specialty care into the homes of individuals with Parkinson disease who have limited access to care; 2. To show that such an approach can improve quality of life; 3. To establish that the telemedicine can enhance the quality of care; and 4. To demonstrate that this remote approach to care saves time, reduces travel, and decreases care partner burden.

Eligibility Criteria

Inclusion Criteria

Individuals with clinically diagnosed Idiopathic Parkinson disease in the judgment of the independent rater
No better alternative explanation for the parkinsonism
Access to a non-public, internet-enabled device (e.g., computer, tablet computer, smart phone) that has the capacity for web-based video conferencing
Be physically located at time visits are conducted in a state where the participating physician is licensed to practice medicine
Have a local care provider that the study team can contact
Live at home, in a senior housing complex, or assisted living facility
Be fluent in English (all participating states) or Spanish (participants in Florida and Massachusetts only)
Willing and able to provide informed consent
Care partner (if applicable) must be able and willing to provide informed consent to participate if he or she so chooses.

Exclusion Criteria

Currently hospitalized
Condition (e.g., prominent psychosis) that precludes study participation as identified by the medical professional (site investigator or nurse).
Participation in another telemedicine study.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02038959). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.